STAT3 and cancer: Both IL-6 and IL-8 have been demonstrated to inhibit antitumor CD8 T-cell responses via recruitment of immunosuppressive myeloid cells or STAT3 activation and arginase-I-mediated suppressive functions of MDSCs in genitourinary and other human cancers (15–18).